RhumbLine Advisers’s Castle Biosciences CSTL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $927K | Buy |
45,397
+6,211
| +16% | +$127K | ﹤0.01% | 2287 |
|
|
2025
Q1 | $784K | Sell |
39,186
-706
| -2% | -$14.1K | ﹤0.01% | 2289 |
|
|
2024
Q4 | $1.06M | Sell |
39,892
-1,009
| -2% | -$26.9K | ﹤0.01% | 2224 |
|
|
2024
Q3 | $1.17M | Sell |
40,901
-995
| -2% | -$28.4K | ﹤0.01% | 2187 |
|
|
2024
Q2 | $912K | Buy |
41,896
+2,988
| +8% | +$65K | ﹤0.01% | 2302 |
|
|
2024
Q1 | $862K | Buy |
38,908
+1,000
| +3% | +$22.2K | ﹤0.01% | 2330 |
|
|
2023
Q4 | $818K | Buy |
37,908
+60
| +0.2% | +$1.3K | ﹤0.01% | 2376 |
|
|
2023
Q3 | $639K | Buy |
37,848
+539
| +1% | +$9.1K | ﹤0.01% | 2460 |
|
|
2023
Q2 | $512K | Sell |
37,309
-1,986
| -5% | -$27.2K | ﹤0.01% | 2671 |
|
|
2023
Q1 | $893K | Buy |
39,295
+1,383
| +4% | +$31.4K | ﹤0.01% | 2174 |
|
|
2022
Q4 | $892K | Buy |
37,912
+393
| +1% | +$9.25K | ﹤0.01% | 2194 |
|
|
2022
Q3 | $978K | Buy |
37,519
+3,239
| +9% | +$84.4K | ﹤0.01% | 2141 |
|
|
2022
Q2 | $752K | Buy |
34,280
+12,344
| +56% | +$271K | ﹤0.01% | 2281 |
|
|
2022
Q1 | $984K | Buy |
21,936
+1,038
| +5% | +$46.6K | ﹤0.01% | 2138 |
|
|
2021
Q4 | $896K | Sell |
20,898
-357
| -2% | -$15.3K | ﹤0.01% | 2254 |
|
|
2021
Q3 | $1.41M | Buy |
21,255
+832
| +4% | +$55.3K | ﹤0.01% | 2072 |
|
|
2021
Q2 | $1.5M | Buy |
20,423
+5,913
| +41% | +$434K | ﹤0.01% | 2079 |
|
|
2021
Q1 | $993K | Buy |
14,510
+1,007
| +7% | +$68.9K | ﹤0.01% | 2191 |
|
|
2020
Q4 | $907K | Buy |
13,503
+1,027
| +8% | +$69K | ﹤0.01% | 2178 |
|
|
2020
Q3 | $642K | Sell |
12,476
-288
| -2% | -$14.8K | ﹤0.01% | 2173 |
|
|
2020
Q2 | $481K | Buy |
12,764
+3,520
| +38% | +$133K | ﹤0.01% | 2361 |
|
|
2020
Q1 | $276K | Buy |
+9,244
| New | +$276K | ﹤0.01% | 2446 |
|